TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05837000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patient will receive 0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patient will receive 0.5ml/kg bupivacaine 0.25% + 0.5mg/kg ketamine caudally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Description: Patient will receive 0.5ml/kg bupivacaine 0.25% + 1ml volume containing 50mg of magnesium caudally.
Study: NCT04677023

Intervention type: OTHER
Group type: OTHER
Intervention: GrandioSO x-tra® bulk
Description: The prepared cavities will be restored with GrandioSO X-tra (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using using Elipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
Study: NCT06648928

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Managed PTSD Coach
Description: A widely available mobile application designed to help individuals manage PTSD symptoms available in English and Spanish.
Study: NCT05453903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleximenib
Description: Participants will receive bleximenib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleximenib
Description: Participants will receive bleximenib.
Study: NCT04677023

Intervention type: OTHER
Group type: OTHER
Intervention: Admira fusion X--tra® bulk
Description: he prepared cavities will be restored with Admira fusion X-tra®️ bulk (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using usingElipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
Study: NCT05453903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleximenib
Description: Participants will receive bleximenib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax (VEN)
Description: Participants will receive VEN.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax (VEN)
Description: Participants will receive VEN.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Description: Participants will receive AZA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Description: Participants will receive AZA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Participants will receive cytarabine.
Study: NCT05740891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T cells injection
Description: Autologous hematopoietic stem cell transplantation combined with BCMA CAR-T cells
Study: NCT05453903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin or Idarubicin
Description: Participants will receive daunorubicin or idarubicin.
Study: NCT05539924

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin 150mg gabapentin 400mg
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg gabapentin 400mg
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg gabapentin 400mg
Description: oral administration
Study: NCT04883918

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASC930
Description: 4 intravenous doses of ASC930
Study: NCT06086457

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 50Gy in 25 fractions to planning gross tumor volume (PGTV) with involved site included.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP or PF regimen depended on investigator's choice.
Description: A maximum of six cycles was recommended for chemotherapy. Chemotherapy Regimen 1(TP regimen A): Nab-paclitaxel(Albumin-bound paclitaxel) 110-130mg/ m2，d1，d8; Cisplatin 60-75mg/ m2，d1；Q3W； Chemotherapy Regimen 2 (TP regimen B): Paclitaxel 150-175 mg/m2, d1; Cisplatin 60-75mg/ m2，d1；Q3W； PD-1 inhibitor 200mg, d1, Q3W Chemotherapy Regimen 3 (PF regimen): Capecitabine 800mg/m2, bid, d1-14; Cisplatin 25-30mg/m2, d1,d2, Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP or PF regimen depended on investigator's choice.
Description: A maximum of six cycles was recommended for chemotherapy. Chemotherapy Regimen 1(TP regimen A): Nab-paclitaxel(Albumin-bound paclitaxel) 110-130mg/ m2，d1，d8; Cisplatin 60-75mg/ m2，d1；Q3W； Chemotherapy Regimen 2 (TP regimen B): Paclitaxel 150-175 mg/m2, d1; Cisplatin 60-75mg/ m2，d1；Q3W； PD-1 inhibitor 200mg, d1, Q3W Chemotherapy Regimen 3 (PF regimen): Capecitabine 800mg/m2, bid, d1-14; Cisplatin 25-30mg/m2, d1,d2, Q3W.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 inhibitor
Description: Camrelizumab (200mg, d1, Q3W) was continued until disease progression, unacceptable toxicity, death, physician or patient decision to withdraw, non-compliance, or discontinuation for administrative reasons (up to 35 cycles).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Camrelizumab (200mg, d1, Q3W) was continued until disease progression, unacceptable toxicity, death, physician or patient decision to withdraw, non-compliance, or discontinuation for administrative reasons (up to 35 cycles).
Study: NCT04524442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arginine/lysine
Description: 1000 milliliters (mL) administered at a constant rate of 250 mL per hour
Study: NCT06345079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cessation of somatostatin analogues
Description: Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of somatostatin analogues
Description: Patients randomised to continue SSA will receive a SSA injection ≥28 days prior to their first cycle of PRRT, during PRRT and will continue receiving SSA every 4 weeks after PRRT.
Study: NCT03760575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg via IV infusion every 3 weeks for 2 cycles 3 pre-surgery, for 4 cycles post-surgery and then every 3 weeks during maintenance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG) Image-Guided Surgery
Description: Standard surgery with image guided resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
Study: NCT06074562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT05688852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX958
Description: Dose A VTX958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX958
Description: Dose B VTX958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VTX958 Placebo
Description: Placebo
Study: NCT06225817

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Open-label placebo pills
Description: The placebo pills in this study are empty capsules without any ingredients inside. The capsules are made of microcrystalline cellulose.
Study: NCT05803421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC once daily
Study: NCT03896750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PA-824
Description: PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PA-824
Description: PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PA-824
Description: PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.
Study: NCT05711940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: COMP360 Psilocybin administered under supportive conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: COMP360 Psilocybin administered under supportive conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: COMP360 Psilocybin administered under supportive conditions
Study: NCT06058702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.036 mg/kg) administered intravenously over 20 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.036 mg/kg) administered intravenously over 20 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Control: Small amount of sterile 190 proof USP ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: Small amount of sterile 190 proof USP ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.
Study: NCT05573568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine
Description: DMT will be administered using a vaporizer device in a single ascending fixed-order dosing regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine
Description: DMT will be administered using a vaporizer device in a single ascending fixed-order dosing regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine
Description: DMT will be administered using a vaporizer device in a single ascending fixed-order dosing regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine
Description: DMT will be administered using a vaporizer device in a single ascending fixed-order dosing regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine
Description: DMT will be administered using a vaporizer device in a single ascending fixed-order dosing regimen
Study: NCT06167772

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA
Description: branched-chain amino acid (bcaa) (ratio valine:leucine:isoleucine = 1.2:2:1) 40 g/day (leucine 19 g/day) form: powdered bcaa sealed in 8 g sachet package or bcaa parenteral 250 mL per bag.~frequency: 1 sachet bcaa dissolved in oral nutrition supplement (standard nutrition) 5 times per day, or bcaa parenteral, or combination of bcaa enteral \& parenteral.~duration: 10 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard nutrition
Description: Target energy of 20 kcal/kg BW/day Target protein ratio protein:non-protein calorie 1:70

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard nutrition
Description: Target energy of 20 kcal/kg BW/day Target protein ratio protein:non-protein calorie 1:70

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy
Description: A symmetric biphasic rectangular pulse was employed, with a frequency of 100 Hz, pulse width of 500 µs, Ton 5 s, Toff 25 s, ramp up of 1 s and ramp down of 1 s.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard physiotherapy
Description: A symmetric biphasic rectangular pulse was employed, with a frequency of 100 Hz, pulse width of 500 µs, Ton 5 s, Toff 25 s, ramp up of 1 s and ramp down of 1 s.
Study: NCT05784103

Intervention type: DEVICE
Group type: OTHER
Intervention: Clarifi Modulum
Description: During consenting period, the Modulim equipment will be calibrated and setup ready for scanning. Subject's volar aspect of the thumb along with the palm surface will be ready to target the optical camera head. Actual scanning takes less than 60 seconds. The images will be processed offline. During processing 3-5 different regions of interest will be taken to measure the oxygen parameters such as tissue oxygen saturation, oxy-hemoglobin, deoxy-hemoglobin, superficial hemoglobin, and sub-surface hemoglobin.

Intervention type: DEVICE
Group type: OTHER
Intervention: Perimed PeriFlux 5000
Description: Transcutaneous oxygen monitoring (TCOM or TcpO2) is a noninvasive, clinically-approved method to obtain skin oxygen levels. The method is quantitative, and measures oxygen delivery to the skin from underlying tissue. Before positioning the electrode, an adhesive fixation ring will be placed on the dry skin on the volar aspect of the thumb and an electrolyte as a contact liquid will be filled half and the probe is aligned into it by rotating clock-wise to fasten it. Recording will be started and waited for the oxygen level to stabilize and a fixed value will be recorded. The probe will be heated to about 45oC. Although this device has other options, only the measurement of O2 will be performed using this device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Apple Watch Oxygen Sensor
Description: The apple watch is equipped with green, red, and infrared LEDs that shine light onto the blood vessels in the wrist, with photodiodes measuring the amount of light reflected back. Apple's algorithms use this information to calculate the color of the blood, which is an indication of how much oxygen is in the blood. Bright red blood is well oxygenated, while darker blood has less oxygen. This can measure blood oxygen levels between 70 and 100 percent. Most healthy people have blood oxygen levels that range from 95 to 100 percent. The apple watch sensor will be positioned on the user's preferred wrist.

Intervention type: DEVICE
Group type: OTHER
Intervention: Innovo iP 900AP
Description: The pulse oximeter enables transcutaneous monitoring of the oxygen saturation of hemoglobin in arterial blood. In this study, volar aspect of thumb and index finder of the subject will be used to measure blood oxygen saturation.
Study: NCT06234072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus + Gemcitabine
Description: Participants will receive Astragalus combined with Gemcitabine. Astragalus, a traditional Chinese medicine, exhibits promising potential in cancer treatment. Studies suggest its role in regulating immune responses, suppressing tumors, and improving overall treatment outcomes in cancer patients. Astragalus combined with chemotherapeutic drug such as Gemcitabine is a popular complementary and alternative therapy used for cancer patients because it can increase therapeutic effects and decrease side effects. This synergistic approach holds potential for more effective and targeted therapeutic outcomes in pancreatic cancer patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine alone
Description: Gemcitabine is a potent chemotherapy drug widely employed in treating various cancers, including pancreatic cancer. As a nucleoside analog, it disrupts DNA synthesis, impeding cancer cell proliferation. Gemcitabine is administered intravenously and has shown efficacy in alleviating symptoms, improving survival rates, and enhancing the quality of life for patients undergoing cancer treatment.
Study: NCT06276049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: custom GPT supported self-directed learning
Description: The intervention in our study involved a LearnGuide utilization guide course along with a 12-week integrated training program that incorporated LearnGuide. In the first two-hour session, instructional staff introduced LearnGuide through a hands-on demonstration, teaching students how to use ChatGPT effectively by crafting high-quality prompts. The team emphasized LearnGuide's role as an AI facilitator in self-directed learning (SDL). Following the introduction, students were assigned various tasks including online learning, literature reviews, case analyses, and Problem-Based Learning (PBL) activities. Over the 12-week SDL phase with LearnGuide, students were required to complete at least one of these tasks weekly. This setup allowed students to consult mentors for any LearnGuide-related questions, enhancing their learning experience.
Study: NCT06423443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy
Description: digital cognitive behavioral therapy app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: traditional on-line health education app

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAU
Description: treatment as usual

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: treatment as usual
Study: NCT05716386

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low salt diet
Description: Low salt diet less than 2 gram per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low salt diet
Description: Low salt diet less than 2 gram per day
Study: NCT05204836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid Injection
Description: 5 mg / 100 mL intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL intravenous infusion
Study: NCT05187546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-PI2620
Description: \[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-PI2620
Description: \[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).
Study: NCT05194605

Intervention type: OTHER
Intervention: Prediction model
Description: We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with osteosarcoma.

Intervention type: OTHER
Intervention: Prediction model
Description: We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with osteosarcoma.
Study: NCT05288855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin
Description: calcineurin inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin
Description: calcineurin inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin
Description: calcineurin inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: matching placebo capsule
Study: NCT05341284

Intervention type: OTHER
Intervention: Questionnaire Survey and Cervical Cancer Screening
Description: A brief questionnaire will be administered to all participants at enrollment and at the pre-scheduled follow-up visit at Month 36.~For the subject who are eligible for the screening (i.e. (1)≥ 18 years old; (2) had sexual debut prior to enrollment, (3) no contradiction to the screening, (4) voluntary to the screening) will be referred to the study site hospitals by offering the subjects a cervical cancer screening voucher, and the type-specific HPV test will be performed as primary screening approach at Month 0 and 36.

Intervention type: OTHER
Intervention: Questionnaire Survey and Cervical Cancer Screening
Description: A brief questionnaire will be administered to all participants at enrollment and at the pre-scheduled follow-up visit at Month 36.~For the subject who are eligible for the screening (i.e. (1)≥ 18 years old; (2) had sexual debut prior to enrollment, (3) no contradiction to the screening, (4) voluntary to the screening) will be referred to the study site hospitals by offering the subjects a cervical cancer screening voucher, and the type-specific HPV test will be performed as primary screening approach at Month 0 and 36.